Clinical Trial Update: Toripalimab Combined With Apatinib Mesylate for the Treatment of Gastric Adenocarcinoma in a Prospective Randomized Multicenter Phase II Clinical Study [Phase 2]

View source ↗

Summary

A prospective randomized multicenter Phase II study evaluating toripalimab combined with apatinib mesylate for gastric adenocarcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Adenocarcinoma

Drugs mentioned

• Apatinib Mesylate (apatinib)
• Toripalimab (Toripalimab)

Snippet

Sponsor: Zhejiang Cancer Hospital | Conditions: Gastric Adenocarcinoma | Phase 2 | Status: UNKNOWN